2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.

ABSTRACT: Diffuse large B cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment. R-CHOP remains the mainstay of therapy and can achieve long-term disease control in nearly 90% of patients presenting with limited-stage and in up to 60% of those presenting with advanced stages. Advances on the understanding of the genetic landscape and molecular features of DLBCL have identified high-risk subsets with poor outcomes to chemo-immunotherapy that are actively being studied in clinical trials. Novel therapies could potentially improve outcomes for patients with high-risk disease. Studies evaluating risk-adapted therapy based on classification by cell of origin (COO) and

SUBMITTER: Susanibar-Adaniya S 

PROVIDER: S-EPMC8172085 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature